Scientific deep-dive

ZUPREME-1: Petrelintide Phase 2 Weight Loss Results

In the phase 2 ZUPREME-1 trial, weekly petrelintide lowered weight by up to 9.8% at 28 weeks and 10.7% at 42 weeks versus 1.7% on placebo, with nausea in 20%. What the doses, estimand and side effects show, and what the trial leaves open.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
8 min read·9 citations

In the phase 2 ZUPREME-1 trial, once-weekly petrelintide lowered body weight by 7.9% to 9.8% at 28 weeks across five doses, compared with 1.7% on placebo, in adults with overweight or obesity and no type 2 diabetes[1]. Those are efficacy-estimand figures, meaning they estimate the effect had people stayed on treatment, and weight loss reached up to 10.7% by week 42[1][2]. Nausea affected 20% of participants on petrelintide versus 6% on placebo, and vomiting was infrequent[1]. Petrelintide remains investigational: its phase 3 trials had only just started in October 2026[7].

About this article. Our petrelintide explainer covers what the drug is and how amylin analogs work. This page looks at the ZUPREME-1 readout itself: the doses, the estimand, the side effects and what the trial leaves unanswered.

How the trial was designed

ZUPREME-1 was a randomized, double-blind, placebo-controlled trial at 32 sites in Poland, Romania and the US[1]. It enrolled adults without type 2 diabetes who had a BMI of at least 30, or at least 27 with hypertension or dyslipidemia[1]. Participants were assigned 5:1 to weekly injections of petrelintide at one of five maintenance doses (1.0 to 9.0 mg) or placebo for 42 weeks, on top of a reduced-calorie diet and increased physical activity[1][8]. Doses went up every four weeks, so escalation took between 4 and 16 weeks[2].

Of 493 people randomized, 485 received at least one dose: 53% female, mean age 47, mean weight 107.1 kg, mean BMI 36.7 and 86% White[1]. The primary endpoint was percentage weight change at week 28, and the trial was funded by Zealand Pharma, whose employees are among the authors[1]. Roche co-develops the drug with Zealand under a licensing agreement[2].

Weight results by dose

Every dose beat placebo at the primary endpoint[1]. The table gives week 28 results from the published abstract and week 42 results from the American Diabetes Association 2026 slides[1][2]. All figures use the efficacy estimand, and the week 42 values were a secondary endpoint[2]. The slides label the arms Dose 1 to Dose 5 rather than in milligrams, so we matched them to the published doses using arm sizes and each arm’s week 28 result; the per-dose side effect figures below rely on the same match.

ZUPREME-1 mean weight change from baseline, efficacy estimand
Maintenance doseWeek 28 (95% CI)Difference vs placebo at week 28 (95% CI)Week 42 (95% CI)
1.0 mg (n=79)−7.9% (−9.0 to −6.7)−6.2 points (−7.9 to −4.5)−8.7% (−10.1 to −7.3)
2.5 mg (n=81)−7.9% (−9.0 to −6.7)−6.2 points (−7.8 to −4.5)−9.2% (−10.6 to −7.8)
5.0 mg (n=83)−9.8% (−10.9 to −8.6)−8.1 points (−9.7 to −6.5)−10.7% (−12.1 to −9.4)
7.0 mg (n=79)−9.3% (−10.5 to −8.2)−7.7 points (−9.3 to −6.0)−10.5% (−11.9 to −9.1)
9.0 mg (n=82)−9.4% (−10.5 to −8.3)−7.7 points (−9.4 to −6.1)−10.2% (−11.6 to −8.8)
Placebo (n=81)−1.7% (−2.8 to −0.5)Not applicable−1.7% (−3.1 to −0.3)

Two things stand out. Going above 5 mg added nothing visible: the 7 mg and 9 mg arms were numerically no better than 5 mg at either timepoint, and the confidence intervals overlap[1][2]. And weight kept declining to week 42[1], though the curves on the ADA slides slow after week 28[2], so 42 weeks does not show where the loss would level off. Each active arm had about 80 people, which suits dose-finding but leaves a lot of uncertainty around the differences between doses.

Roche’s topline release said women lost considerably more weight than men, without giving numbers[3]. The sex split matters when comparing this trial with others, as discussed below.

Why the estimand matters here

The ADA slides define the efficacy estimand as the treatment effect if all participants had stayed on the study drug and not started another obesity treatment[2]. That is a best-case framing, because some people do stop. In ZUPREME-1, total treatment discontinuation for any reason by week 42 was 15.5%, ranging from 9.6% to 18.3% across petrelintide arms, versus 24.7% on placebo[2].

The companion estimate, the treatment-regimen estimand, counts what happened regardless of whether people stayed on the drug. Roche described those results as “largely consistent” with the efficacy estimand[3], but neither the published abstract nor the ADA slides give the treatment-regimen percentages[1][2]. The full Lancet paper may report them, but this review draws on its abstract. For now, read the figures above as what the drug does in people who keep taking it.

Side effects: the tolerability claim, examined

The authors concluded that petrelintide had gastrointestinal tolerability similar to placebo “apart from predominantly mild nausea during dose escalation”[1]. That exception is a real one: nausea was about three times as common on the drug, at 79 of 404 participants (20%) versus 5 of 81 (6%)[1]. The other GI numbers were closer. Vomiting occurred in 3% on petrelintide and 6% on placebo, diarrhea in 7% and 7%, and constipation in 7% and 4%[1].

The pooled numbers hide some variation across doses. Nausea ranged from 12.3% at 2.5 mg to 28.0% at 9 mg, without a straight line between them, and vomiting reached 8.5% at 9 mg while the 2.5 mg and 5 mg arms had none[2]. Constipation reached 12.7% at 7 mg[2]. About 77% of GI events on petrelintide were mild, and most were reported during escalation[2]. The placebo arm had only 81 people, so its percentages shift noticeably with a few events.

Selected adverse events through week 51, pooled petrelintide vs placebo (ADA 2026 slides)
EventPetrelintide (n=404)Placebo (n=81)
Any adverse event70.8%69.1%
Serious adverse event3.5%3.7%
Severe adverse event3.5%6.2%
Stopped due to any adverse event4.5%4.9%
Stopped due to a GI adverse event1.5%0%
Nausea19.6%6.2%
Fatigue7.7%4.9%
Injection site reactions7.2%6.2%
Alopecia (hair loss)4.7%1.2%

The abstract does not mention alopecia[1], but the ADA slides list it: 4.7% on petrelintide versus 1.2% on placebo, and 10.1% in the 7 mg arm[2]. The placebo figure is a single case and there is no clear dose pattern, so the trial can’t say whether the drug causes it or whether it tracks with rapid weight loss, a question our review of GLP-1 hair loss covers for approved drugs. No deaths were reported[1].

Slower dose escalation may be part of the tolerability story. Roche noted nausea was less common than in the 16-week phase 1b trial, which escalated every two weeks[3]; that trial reported nausea in 16.7% to 33.3% of people on petrelintide and 16.7% on placebo[4]. These are separate trials with small early-phase arms, so the comparison is only suggestive.

Other secondary results

At week 42, waist circumference fell by 7.9 to 10.8 cm across doses versus 4.3 cm on placebo, high-sensitivity CRP fell by 17% to 41% versus 6%, and triglycerides fell by 12% to 21% versus 9%[2]. These came from a phase 2 trial in people without diabetes and are not evidence of fewer heart attacks or strokes. The registered secondary endpoints also include HbA1c, fasting glucose and categorical weight-loss thresholds of 5% and 10%[8]. Those results are not given in the abstract or the slides reviewed here.

How it looks next to eloralintide

The natural comparison is eloralintide, Lilly’s amylin receptor agonist, because its phase 2 trial also reported an efficacy estimand in people without diabetes. There, weight fell by 20% at 9 mg over 48 weeks (95% CI −22.7 to −17.5) versus 0.4% on placebo[5]. That is numerically larger than petrelintide’s 10.7% at week 42[2], but no trial has compared them head to head.

Two amylin phase 2 trials, side by side (indirect comparison only)
MeasureZUPREME-1 (petrelintide)Eloralintide phase 2
Participants485 dosed263 randomized
Duration42 weeks48 weeks
Female53%78%
Mean BMI36.739.1
Largest mean weight change, efficacy estimand−10.7% (5 mg, week 42)−20% (9 mg and 6–9 mg, week 48)
Placebo−1.7%−0.4%
Nausea19.6% pooled (12.3% to 28.0% by dose)11% to 64% by dose; placebo 14%
FunderZealand PharmaEli Lilly

The trials differ in ways that could move the numbers. Eloralintide’s population had a higher BMI, ran six weeks longer and was 78% female versus 53%[1][5], and Roche has said women lost considerably more weight than men in ZUPREME-1[3]. Nausea rates in the eloralintide trial reached 64% at the 6 mg dose but were 33% at 9 mg and 25% with 3 to 9 mg escalation[5]. A 2026 review in Pharmacological Research argues that receptor selectivity, exposure kinetics and brain circuitry may all shape tolerability across this class, and treats that as an open question[6].

What the trial can’t tell you

  • Long-term durability. Treatment lasted 42 weeks with safety follow-up to week 51[1][2], and weight was still declining through week 42[1]. It says nothing about maintenance or regain after stopping.
  • Outcomes beyond weight. Lower hsCRP and triglycerides are markers[2]. A dedicated phase 3 trial in people with established cardiovascular disease is part of the program[7].
  • How it compares to a GLP-1. ZUPREME-1 had no active comparator[1], so any ranking against semaglutide or tirzepatide is indirect.
  • Independence. The sponsor funded the trial, five of the eleven authors are Zealand employees and equity holders, and all authors reported medical writing support from Zealand[1].

What comes next

A second phase 2 trial, ZUPREME-2, enrolled 220 people with overweight or obesity and type 2 diabetes. In an October 2026 company announcement of topline data, Zealand reported efficacy-estimand weight loss of 7.4% to 9.2% at week 28 versus 2.0% on placebo, and placebo-adjusted HbA1c reductions of 0.61% to 0.88%[7]. The same announcement says three phase 3 trials have started, expected to enroll about 7,000 people in total: ZUPREME-3 (without diabetes), ZUPREME-4 (with type 2 diabetes) and ZUPREME-5 (with established cardiovascular disease)[7]. ZUPREME-3 is registered at about 3,900 participants with weight change at week 64 as its primary outcome[9], so it should provide longer data against placebo. It is not registered as a comparison with a GLP-1 drug.

For anyone interested in the drug now, the realistic route is a clinical trial. Petrelintide is investigational, and anything sold online under the name is not the trial drug. People weighing their options can ask a prescriber how the weight loss and side-effect profile of approved medications compare with their own goals, and whether a trial near them is recruiting.

Frequently Asked Questions

At the primary endpoint of 28 weeks, mean weight change ranged from −7.9% to −9.8% across five doses, versus −1.7% on placebo. By week 42 the best-performing arm, 5 mg, reached −10.7%. These figures use the efficacy estimand, which assumes people stayed on treatment.
Nausea was the most common, affecting about 20% on petrelintide versus 6% on placebo, and it was predominantly mild and concentrated during dose escalation. Vomiting occurred in 3% versus 6%, diarrhea in 7% in both groups, and constipation in 7% versus 4%. Hair loss was reported in 4.7% versus 1.2%.
ZUPREME-1 can’t answer that, because it compared petrelintide only with placebo. Its 42-week weight loss of up to 10.7% comes from a different population and time frame than the phase 3 trials of approved drugs, so direct number comparisons can mislead.
This trial can’t give a date. Petrelintide is investigational, and its phase 3 program in three populations started in 2026. ZUPREME-3, the main obesity trial, is registered with an estimated primary completion date in late 2028, and regulators would still need to review the results. Anything sold today under the name is not the trial drug.

References

  1. 1.Garvey WT, Ard J, Connery L, Frias JP, le Roux CW, Pietiläinen KH, Dinesen M, Hagen BF, Larsen L, Hesse D, Kendall DM. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026. PMID: 42810355.
  2. 2.Garvey WT, Connery L, Dinesen M, Hagen BF, Larsen L, Hesse D. Petrelintide, a human amylin analog for the treatment of obesity: efficacy and safety from the Phase 2 trial, ZUPREME-1 (poster and slides). American Diabetes Association 2026 Scientific Sessions, ePoster Theater 3083-LB. 2026. https://www.zealandpharma.com/media/4lzjvdba/garvey-et-al_zupreme1_ada2026_poster_and_slides.pdf
  3. 3.Roche. Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity (March 5, 2026). Roche media release. 2026. https://www.roche.com/media/releases/med-cor-2026-03-05
  4. 4.Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, Heise T. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. PMID: 42017294.
  5. 5.Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, Butler A, Kazda C, Mather KJ, Coskun T. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. PMID: 41207310.
  6. 6.Fischer SL, Borner T. Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. Pharmacol Res. 2026. PMID: 42586227.
  7. 7.Zealand Pharma. Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes (Company announcement No. 54/2026, October 7, 2026). Company announcement. 2026. https://www.inderes.fi/releases/zealand-pharma-announces-positive-phase-2-zupreme-2-topline-results-for-amylin-analog-petrelintide-in-people-with-overweight-or-obesity-and-type-2-diabetes
  8. 8.Zealand Pharma. Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities (ZUPREME). NCT06662539. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT06662539
  9. 9.Hoffmann-La Roche. A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity (ZUPREME-3). NCT07843498. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07843498

What Is Petrelintide? Zealand's Long-Acting Amylin Analog

Petrelintide is Zealand Pharma's investigational long-acting amylin analog, with published human data through phase 2. We cover what amylin analogs are for, how early 'early' really is, and why early-phase figures cannot be compared to phase 3 results.

5 min read

Zenagamtide Pill vs Shot: What the Phase 2 Lancet Reports Found

Two Lancet reports tested daily oral and weekly injected zenagamtide (amycretin) in type 2 diabetes. Here is how HbA1c, company-reported weight loss and side effects compare, and why the comparison is still indirect.

7 min read

What Is Eloralintide? Lilly's Amylin Weight-Loss Drug Explained

Eloralintide is Eli Lilly's investigational once-weekly amylin drug. In a 48-week phase 2 trial people lost about 20% of body weight on higher doses, with nausea and fatigue as the main side effects. How it works, the trial results, and the phase 3 timeline.

7 min read

What Is Cagrilintide? The Amylin Analog Behind CagriSema

Cagrilintide is a once-weekly amylin analog from Novo Nordisk and the other half of CagriSema. Neither has FDA approval. We cover what amylin analogs actually are, the pooled trial evidence across 5,425 participants, and why there is no cagrilintide dosage chart to follow.

6 min read

REDEFINE: The Full CagriSema Trial Program (2026)

The full CagriSema REDEFINE program: REDEFINE 1 (22.7% adherent weight loss), REDEFINE 2 in diabetes, and the REDEFINE 4 head-to-head miss versus tirzepatide.

13 min read

SYNCHRONIZE-1: Survodutide Phase 3 Obesity Results Explained

Survodutide produced mean weight changes of -12.2% and -13.0% at 76 weeks versus -5.4% on placebo in its NEJM phase 3 trial. Here is what those numbers mean, why 16.6% also circulates, and what remains unknown.

8 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $99/mo

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $139/mo

4-month plan rate

Get started →
7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Read full review →

From $149/mo

+ required membership

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →